GlaxoSmithKline reported Tuesday at the American Association for the Study of Liver Diseases annual meeting that in two late-stage trials, its experimental drug eltrombopag helped patients with thrombocytopenia achieve "statistically significant" improvement in sustained virological response (SVR).
"The ENABLE trials provide insight into a population that has generally been excluded from clinical trials because they are unable to initiate interferon therapy," remarked Rafael Amado, senior vice president of Oncology Development at GlaxoSmithKline.
No comments:
Post a Comment